What are the top MedTech startups by total funding raised?

Everything we know about the MedTech market, in one place. Get our report whether you build or invest.
Summary
The top MedTech startups by total funding raised are MiRus and Freenome, tied at $1.6B each, followed by Neuralink ($1.3B), CMR Surgical ($1.2B), and Neko Health ($1.0B). Together, these five companies have attracted $6.7B, spanning medical implants, cancer detection, brain-computer interfaces, surgical robotics, and preventive healthcare.
The 97 startups in our ranking account for approximately $30.1B in cumulative funding. The ten largest companies have raised $9.405B, with MiRus and Freenome alone accounting for a particularly large share of the money at the top.
MiRus's position is unusual. Boston Scientific's $1.5B strategic investment in May 2026 represents almost its entire reported funding history, giving the company an exceptionally large financing total through a single transaction.
Freenome has followed a very different path. It raised $1.6B across ten rounds before going public in July 2026, combining extensive private financing with a $240M PIPE and clinical progress in blood-based colorectal cancer screening.
Neuralink and CMR Surgical illustrate why advanced medical technologies require so much capital. Brain-computer interfaces and surgical robots involve years of engineering, clinical development, regulatory work, and hospital adoption before they can become large commercial businesses.
Neko Health's $1.0B fundraising history shows that preventive healthcare is becoming a serious MedTech investment category. Its $700M Series C in July 2026 reflects investor appetite for consumer-facing scanning services, although the long-term clinical benefits of broad preventive screening still need to be demonstrated.
Medical AI has established a substantial position of its own. Aidoc ($524M), Cleerly ($403M), PathAI ($258M), and Viz.ai ($254M) are among the leading companies, targeting imaging, cardiovascular diagnostics, pathology, and clinical coordination.
MedTech financing has recovered, but the headline figures need context. EY reported $63B in sector financing for the twelve months ending June 2026, up 87% year over year, although IPOs and debt accounted for approximately 80% of that capital. Private medical-device venture investment has remained healthy without matching its previous record pace.
The United States dominates the highest funding positions, but Europe has produced serious competitors. The UK's CMR Surgical has raised $1.2B, Sweden's Neko Health $1.0B, and Switzerland's CeQur $492M, while Israel and China also have several heavily funded specialists.
IPO activity and acquisitions are giving investors more ways to exit. Freenome, Saluda Medical, and Edge Medical Robotics have reached public markets, while Nalu Medical and VitalConnect have been acquired. These outcomes also show that large funding totals can lead to very different commercial destinations.
Ultimately, the MedTech funding race is being won by companies that have attracted exceptional investor commitments, but the next stage will be harder. Clinical evidence, regulatory authorization, reimbursement, hospital adoption, and repeatable sales will determine which of these heavily funded startups become lasting healthcare businesses.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us

In our report covering the medtech market, you will always find fresh funding data, taken straight from our own verified funding database.
Top startups in the MedTech market ranked by total funding raised
Here is an updated table that ranks the top startups in the MedTech market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
If you need to dig deeper and get more detailed data, please check our report covering the MedTech market.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence | Country |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MiRus | Advanced cardiovascular and orthopedic implants | $1.6B1 | 2 | May 2026 | $1.5B | Strategic Minority Equity | Boston Scientific | Active | Strong | United States |
| 2 | Freenome | AI-enabled blood-based cancer screening | $1.6B | 10 | July 2026 | $240M | PIPE | Perceptive Advisors, RA Capital, ADAR1 Capital | IPO | Strong | United States |
| 3 | Neuralink | Implantable brain-computer interfaces | $1.3B | 5 | June 2025 | $650M | Series E | Founders Fund, ARK Invest, Sequoia Capital | Active | Strong | United States |
| 4 | CMR Surgical | Robotic-assisted minimally invasive surgery | $1.2B | 7 | October 2026 | $400M | Strategic Preferred Equity | Trinity Capital, Existing Investors | Active | Strong | United Kingdom |
| 5 | Neko Health | Preventive full-body health scanning | $1.0B | 3 | July 2026 | $700M | Series C | Lightspeed Venture Partners, O.G. Venture Partners, Atomico | Active | Full | Sweden |
| 6 | Saluda Medical | Closed-loop spinal cord stimulation devices | $680M2 | 8 | December 2025 | $150M | IPO | Redmile Group, Wellington Management, Action Potential Venture Capital | IPO | Strong | United States |
| 7 | Aidoc | AI-powered medical imaging diagnostics | $524M | 9 | April 2026 | $150M | Series E | Goldman Sachs, General Catalyst, SoftBank | Active | Strong | Israel |
| 8 | Mevion Medical Systems | Compact proton cancer therapy systems | $516.1M | 9 | June 2018 | $150M | Growth Equity | YuanMing Capital, China Everbright, HOPU Investments | Active | Partial | United States |
| 9 | RefleXion Medical | Biology-guided cancer radiotherapy systems | $493M | 7 | November 2023 | $105M | Series F | The Rise Fund, Ally Bridge Group, Pfizer Venture Investments | Active | Strong | United States |
| 10 | CeQur | Wearable insulin delivery devices | $492M | 6 | June 2026 | $100M | Series E | Undisclosed | Active | Strong | Switzerland |
| 11 | Visby Medical | Rapid portable PCR diagnostic tests | $478M | 7 | June 2025 | $55M | Series F | Catalio Capital Management, ND Capital, Cedars-Sinai | Active | Partial | United States |
| 12 | Edge Medical Robotics | Robotic minimally invasive surgery systems | $462M | 7 | January 2026 | $154M | IPO | Public Offering Investors | IPO | Strong | China |
| 13 | Cornerstone Robotics | Robotic-assisted surgical systems | $460M | 6 | September 2026 | Undisclosed | Strategic Investment | Medtronic | Active | Partial | Hong Kong |
| 14 | Imperative Care | Stroke and vascular intervention devices | $446.4M | 6 | July 2024 | $73M | Series E | Ally Bridge Group, Catalio Capital Management, D1 Capital Partners | Active | Strong | United States |
| 15 | Science Corporation | Neural interfaces and retinal implants | $416M | 4 | March 2026 | $230M | Series C | Lightspeed Venture Partners, Khosla Ventures, Y Combinator | Active | Partial | United States |
| 16 | Quanta Dialysis Technologies | Portable hemodialysis systems | $410M | 5 | November 2024 | $60M | Series E | Novo Holdings, Glenview Capital, b2venture | Active | Strong | United Kingdom |
| 17 | Precision Neuroscience | Minimally invasive brain-computer interfaces | $406M | 4 | September 2026 | $250M | Series D | Pershing Square, Ackman Oxman Institute, B Capital | Active | Strong | United States |
| 18 | Cleerly | AI-powered cardiovascular imaging diagnostics | $403M | 5 | December 2024 | $106M | Series C Extension | Battery Ventures, Insight Partners | Active | Strong | United States |
| 19 | Sword Health | AI-powered digital healthcare and rehabilitation | $365M | 8 | June 2025 | $40M | Series F | General Catalyst, Khosla Ventures, Comcast Ventures | Active | Strong | United States |
| 20 | SetPoint Medical | Implantable therapies for autoimmune diseases | $351M | 12 | March 2025 | $115M | Series D | Elevage Medical Technologies, Ally Bridge Group, NEA | Active | Strong | United States |
| 21 | JenaValve | Transcatheter aortic valve replacement systems | $349M3 | 10+ | August 2022 | $100M | Series C | Bain Capital Life Sciences, QIA, Innovatus Capital Partners | Active | Partial | United States |
| 22 | Medical Microinstruments | Robotic microsurgery and supermicrosurgery | $335M | 4 | October 2026 | $125M | Series D | BioStar Capital, S3 Ventures, Angelini Ventures | Active | Strong | United States |
| 23 | DELFI Diagnostics | AI-powered blood-based cancer detection | $331M | 4 | June 2024 | Undisclosed | Strategic Equity | Merck Global Health Innovation Fund | Active | Strong | United States |
| 24 | Karius | Blood-based infectious pathogen detection | $329M | 4 | May 2024 | $100M | Series C | 5AM Ventures, Gilde Healthcare, Khosla Ventures | Active | Strong | United States |
| 25 | Synchron | Minimally invasive brain-computer interface implants | $325M | 4 | September 2026 | Undisclosed | Series D Extension | Alumni Ventures | Active | Strong | United States |
| 26 | Lumicell | Fluorescence-guided cancer surgery imaging | $320M | 6 | May 2025 | $198M | Series F | BlueIO, Index Ventures, LaunchCapital | Active | Partial | United States |
| 27 | Exo | Handheld ultrasound and imaging software | $308M | 6 | July 2021 | $220M | Series C | RA Capital, BlackRock, Sands Capital | Active | Strong | United States |
| 28 | DentalMonitoring | AI-powered remote orthodontic monitoring | $307M | 5 | February 2026 | $100M | Growth Equity | Lazard Elaia Capital, ISALT, Fonds Stratégique des Transitions | Active | Strong | France |
| 29 | Distalmotion | Robotic-assisted minimally invasive surgery | $300M | 5 | January 2026 | Undisclosed | Strategic Equity | Johnson & Johnson Innovation – JJDC | Active | Partial | Switzerland |
| 30 | Huma | Digital patient monitoring and clinical platforms | $300M+ | 6+ | February 2026 | Undisclosed | Venture Equity | Ascot Capital Partners | Active | Partial | United Kingdom |
| 31 | Earlens | Light-driven hearing aid technology | $299M | 9 | February 2025 | $8M | Series D-II | Undisclosed | Active | Partial | United States |
| 32 | Harbinger Health | Blood-based early cancer detection | $290M | 3 | January 2025 | $100M | Series B-II | Undisclosed | Active | Partial | United States |
| 33 | Caresyntax | Surgical intelligence and workflow software | $288M | 5 | August 2024 | $80M | Series C Extension | Symbiotic Capital, MTIP, Pictet | Active | Strong | United States |
| 34 | AliveCor | Portable ECG and cardiac monitoring | $277.2M | 7 | August 2022 | $150M | Series F | GE Healthcare, Pegasus Tech Ventures, Khosla Ventures | Active | Strong | United States |
| 35 | restor3d | Personalized 3D-printed orthopedic implants | $276M | 10 | August 2025 | $104M | Growth Equity | Partners Group | Active | Partial | United States |
| 36 | Cardiac Dimensions | Minimally invasive heart failure treatments | $275M | 10 | March 2025 | $53M | Series E | Ally Bridge Group, Claret Capital Partners, Hostplus | Active | Partial | United States |
| 37 | Iterative Health | AI-assisted gastrointestinal diagnostics | $264M | 4 | April 2026 | $77M | Series C | GV, Intrepid Growth Partners, Insight Partners | Active | Strong | United States |
| 38 | Noah Medical | Robotic lung diagnostic systems | $262M | 2 | September 2025 | $112M | Series B-2 | Undisclosed | Active | Partial | United States |
| 39 | PathAI | AI-powered digital pathology | $258M | 6 | May 2021 | $165M | Series C | D1 Capital Partners, Kaiser Permanente, General Atlantic | Active | Strong | United States |
| 40 | Moximed | Implantable knee joint shock absorbers | $257.5M | 7 | August 2024 | $61M | Series D | Elevage Medical Technologies, Cormorant Asset Management, Warren Point Capital | Active | Strong | United States |
| 41 | Viz.ai | AI-powered disease detection and coordination | $254M | 8 | April 2022 | $100M | Series D | Tiger Global, Insight Partners, GV | Active | Strong | United States |
| 42 | 4C Medical Technologies | Minimally invasive heart valve replacement | $250M | 9 | March 2025 | $71.6M | Series D | Boston Scientific | Active | Strong | United States |
| 43 | THINK Surgical | Robotic systems for orthopedic surgery | $249.1M | 5 | January 2026 | $45M | Series F-2 | Undisclosed | Active | Partial | United States |
| 44 | Biolinq | Continuous biomarker monitoring biosensors | $247M | 8 | April 2025 | $100M | Series C | Alpha Wave Ventures, RiverVest, AXA IM Alts | Active | Partial | United States |
| 45 | Galvanize Therapeutics | Energy-based therapeutic medical devices | $243M | 3 | September 2025 | $100M | Series C | Sofinnova Partners, Norwest, Elevage | Active | Strong | United States |
| 46 | Intuity Medical | Automatic blood glucose monitoring | $243M | 9+ | May 2019 | $26M | Series I | Versant Ventures, USVP, PTV Healthcare Capital | Active | Partial | United States |
| 47 | Supira Medical | Percutaneous ventricular assist devices | $241M | 5 | March 2025 | $120M | Series E | Novo Holdings, Qatar Investment Authority, Cormorant Asset Management | Active | Full | United States |
| 48 | Beacon Biosignals | AI-powered brain activity diagnostics | $238M | 5 | September 2026 | $110M | Series B-2 | Undisclosed | Active | Partial | United States |
| 49 | Cognito Therapeutics | Non-invasive Alzheimer's neurotechnology | $233M | 4 | March 2026 | $105M | Series C | Morningside Ventures, IAG Capital Partners, Starbloom Capital | Active | Partial | United States |
| 50 | HistoSonics | Noninvasive ultrasound tumor destruction | $230M | 6 | June 2026 | Undisclosed | Undisclosed Equity | Yosemite, Reed Jobs | Active | Partial | United States |
| 51 | TytoCare | Remote medical examinations and diagnostics | $229M | 9 | July 2026 | $25M | Growth Equity | Insight Partners, OrbiMed, Qualcomm Ventures | Active | Strong | United States |
| 52 | Tissium | Biodegradable polymers for tissue reconstruction | $227M | 7 | December 2025 | $34M | Series D2 | Undisclosed | Active | Strong | France |
| 53 | SIBIONICS | Continuous glucose monitoring and biosensors | $226M | 8 | December 2022 | $72M | Series D | Shanghai Healthcare Capital, Industrial Securities Capital, China New Town Development | Active | Partial | China |
| 54 | Truvian | Automated blood testing diagnostic systems | $225M | 5 | July 2024 | $74M | Series D | GreatPoint Ventures, DNS Capital, 7wire Ventures | Active | Partial | United States |
| 55 | Kardium | Pulsed-field atrial fibrillation treatment | $219M | 3+ | July 2025 | Undisclosed | Growth Financing | Janus Henderson, QIA, Eventide Asset Management | Active | Partial | Canada |
| 56 | binx health | Rapid molecular diagnostic testing | $218M | 6 | April 2024 | Undisclosed | Series F | Hildred Capital Management, EQT Life Sciences, OrbiMed | Active | Partial | United States |
| 57 | Route 92 Medical | Neurovascular stroke treatment devices | $217.3M | 8 | April 2026 | $50M | Series F-2 | Novo Holdings, Sectoral Asset Management, Norwest Venture Partners | Active | Strong | United States |
| 58 | Xeltis | Regenerative blood vessels and implants | $216M | 10 | July 2026 | $23M | Series E | Horizon 3 Healthcare, EQT Life Sciences, DaVita | Active | Partial | Netherlands |
| 59 | Infervision | AI-powered medical imaging diagnosis | $215M | 6+ | August 2021 | $140M | Series D | Goldman Sachs Asset Management, CCB Trust, Qiming Venture Partners | Active | Partial | China |
| 60 | Cytovale | Rapid blood-based sepsis diagnostics | $211M | 7 | October 2024 | $100M | Series D | Sands Capital, CPP Investments, Norwest | Active | Partial | United States |
| 61 | FIRE1 | Remote heart-failure monitoring devices | $201M | 5 | January 2025 | $120M | Growth Financing | Polaris Partners, Elevage, Sands Capital | Active | Strong | Ireland |
| 62 | Nalu Medical | Miniaturized chronic pain neurostimulation | $201M | 4 | March 2024 | $20M | Series E Extension | B Capital | Acquired | Partial | United States |
| 63 | MeMed | Rapid host-response infection diagnostics | $199M | 5 | August 2021 | $93M | Series E | La Maison Partners, Phoenix Insurance, OurCrowd | Active | Strong | Israel |
| 64 | CereVasc | Minimally invasive neurological medical devices | $198.9M | 4 | June 2026 | $85M | Series C | Bain Capital Life Sciences, Perceptive Xontogeny | Active | Strong | United States |
| 65 | Cala Health | Wearable neuromodulation therapies | $198M | 7 | April 2026 | Undisclosed | Growth Capital | Trinity Capital | Active | Partial | United States |
| 66 | ZAP Surgical Systems | Robotic non-invasive brain radiosurgery | $195M4 | 4 | October 2026 | $36M | Series F | Catalio Capital Management, Baheal Pharmaceutical Group | Active | Partial | United States |
| 67 | Click Therapeutics | Prescription digital therapeutics software | $190M | 7 | April 2026 | $50M | Series D | Boehringer Ingelheim | Active | Partial | United States |
| 68 | Endogenex | Endoscopic type 2 diabetes treatment | $190M | 7 | March 2026 | $50M | Series C Extension | Arboretum Ventures | Active | Partial | United States |
| 69 | ForSight Robotics | Robotic ophthalmic surgery systems | $190M | 3 | June 2025 | $125M | Series B | Eclipse Ventures, Adani Group, Reiya Ventures | Active | Full | Israel |
| 70 | Elucid | AI cardiovascular imaging software | $185M | 7 | September 2026 | $55M | Series D | IAG Capital Partners, Elevage Medical Technologies | Active | Strong | United States |
| 71 | Neocis | Robot-assisted dental implant surgery | $183M | 8 | January 2024 | $20M | Growth Equity | Mirae Asset Capital, NVentures | Active | Strong | United States |
| 72 | Pulnovo Medical | Pulmonary hypertension intervention devices | $180M | 5 | April 2026 | $100M | Series D / Strategic Equity | Medtronic, EQT, Qiming Venture Partners | Active | Partial | United States |
| 73 | Alleviant Medical | Minimally invasive heart failure devices | $180M | 4 | January 2025 | $91M | Series D | Gilde Healthcare, Vensana Capital, S3 Ventures | Active | Partial | United States |
| 74 | Osler Diagnostics | Handheld rapid diagnostic testing | $180M | 5 | November 2022 | $90M | Series C | Oxford Science Enterprises, Lansdowne Partners, M&G Investments | Active | Strong | United Kingdom |
| 75 | Magenta Medical | Minimally invasive cardiac support pumps | $177M | 5 | July 2024 | $105M | Series E | Novo Holdings, NEA, Viking Global Investors | Active | Partial | Israel |
| 76 | Prenuvo | Whole-body preventive MRI screening | $176M | 2 | February 2025 | $120M | Series B | Forerunner Ventures, Left Lane Capital, Felicis | Active | Strong | United States |
| 77 | Owlstone Medical | Breath-based disease detection diagnostics | $175M | 9 | January 2025 | $27M | Series E | Ventura Capital, Aviva Ventures, Horizons Ventures | Active | Partial | United Kingdom |
| 78 | Monteris Medical | MRI-guided laser brain surgery | $169M | 9 | March 2026 | $28M | Series E | InnovaHealth Partners, Birchview Capital, OSF Ventures | Active | Partial | United States |
| 79 | Eko Health | AI-enabled cardiac monitoring devices | $168M | 9 | June 2024 | $41M | Series D | Highland Capital, Artis Ventures, Questa Capital | Active | Strong | United States |
| 80 | Corvia Medical | Transcatheter heart failure treatment devices | $163.3M | 7 | June 2025 | $55M | Growth Equity | Third Rock Ventures, General Catalyst, Accelmed | Active | Partial | United States |
| 81 | Geneoscopy | RNA-based colorectal cancer screening | $156M | 5 | January 2025 | $105M | Series C | Bio-Rad, Petrichor, Labcorp | Active | Partial | United States |
| 82 | LightForce Orthodontics | Customized 3D-printed orthodontic braces | $151M | 5 | August 2023 | $80M | Series D | Ally Bridge Group, Kleiner Perkins, Matrix Partners | Active | Strong | United States |
| 83 | Capstan Medical | Robotic heart valve surgery | $150M | 4 | December 2024 | $110M | Series C | Eclipse Ventures, Gideon Strategic Partners, Intuitive Ventures | Active | Partial | United States |
| 84 | VitalConnect | Wearable cardiac and patient monitoring | $148M5 | 5 | February 2025 | $50M | Series G | MVM Partners, EW Healthcare Partners, Ally Bridge Group | Acquired | Partial | United States |
| 85 | Aerin Medical | Minimally invasive ENT medical devices | $145.2M | 9 | January 2025 | $32.5M | Growth Equity | KCK MedTech, Questa Capital, OrbiMed | Active | Strong | United States |
| 86 | Augmedics | Augmented reality surgical navigation | $144M | 6 | June 2023 | $83M | Series D | HIG Capital, Almeda Ventures, Revival Healthcare Capital | Active | Strong | United States |
| 87 | HighLife Medical | Transcatheter mitral valve replacement | $144M | 4 | September 2026 | $92M | Growth Equity | Andera Partners, Sofinnova Partners, Mérieux Equity Partners | Active | Partial | France |
| 88 | MicroTransponder | Vagus nerve stimulation for stroke recovery | $141M | 13+ | May 2026 | $150M | IPO | US Venture Partners, Gilde Healthcare, Longitude Capital | IPO | Partial | United States |
| 89 | Virtual Incision | Miniaturized robotic minimally invasive surgery | $141M | 8 | September 2023 | $30M | Series C Extension | Arboretum Ventures, Baird Capital, Endeavour Vision | Active | Partial | United States |
| 90 | Digital Diagnostics | Autonomous AI medical diagnostics | $137M | 6 | August 2022 | $75M | Series B | KKR, 8VC, Cedar Pine | Active | Partial | United States |
| 91 | Proscia | Digital pathology and AI software | $129M | 7 | March 2025 | $50M | Series D | Insight Partners, Alpha Intelligence Capital, Triangle Peak Partners | Active | Full | United States |
| 92 | Scopio Labs | AI-powered digital blood cell microscopy | $125M | 5 | July 2025 | $10M | Series D Extension | Viola Growth | Active | Strong | Israel |
| 93 | Sight Diagnostics | AI-powered rapid blood testing devices | $124M | 5 | July 2020 | $71M | Series D | Koch Disruptive Technologies, Longliv Ventures, OurCrowd | Shutdown | Strong | Israel |
| 94 | Qure.ai | AI-powered medical imaging diagnostics | $121M | 3 | September 2024 | $65M | Series D | Lightspeed Venture Partners, 360 ONE Asset, Merck Global Health Innovation Fund | Active | Strong | India |
| 95 | Ultromics | AI-powered cardiac ultrasound diagnostics | $116M | 6 | July 2025 | $55M | Series C | Legal & General, Allegis Capital, Lightrock | Active | Strong | United Kingdom |
| 96 | Ibex Medical Analytics | AI-powered digital pathology cancer diagnostics | $107M | 4 | September 2023 | $55M | Series C | 83North, Sienna Venture Capital, aMoon | Active | Strong | Israel |
| 97 | GeneCast | Liquid-biopsy cancer diagnostics | $22M | 4 | June 2024 | Undisclosed | Pre-IPO | Undisclosed | Active | Partial | South Korea |
- Mostly a $1.5B strategic minority investment.
- Includes $150M of new shares from its 2025 IPO.
- Published total does not fully match individual rounds.
- Minimum: earlier equity is not fully known.
- Minimum: several intervening equity rounds have unknown amounts.

In our research about medical devices, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.
Which MedTech startups have raised the most funding?
MiRus and Freenome are tied at the top of our MedTech funding ranking, with $1.6B raised each. Neuralink follows with $1.3B, ahead of CMR Surgical at $1.2B and Neko Health at $1.0B.
The five leaders have attracted $6.7B combined. They also represent very different parts of healthcare: MiRus develops medical implants and devices, Freenome focuses on cancer detection, Neuralink builds brain-computer interfaces, CMR Surgical develops surgical robots, and Neko Health offers preventive scanning services.
MiRus reached its total through just two recorded rounds, largely thanks to Boston Scientific's $1.5B strategic minority investment in May 2026. Freenome accumulated the same amount across ten rounds and went public in July 2026. Its latest recorded financing was a $240M PIPE.
Neuralink's $650M Series E in June 2025 and Neko Health's $700M Series C in July 2026 also stand out. Both demonstrate how much investors are willing to commit to technologies that could change the way healthcare is delivered.
| Rank | MedTech startup | Total raised | Rounds | Current stage |
|---|---|---|---|---|
| 1 | MiRus | $1.6B | 2 | Active |
| 2 | Freenome | $1.6B | 10 | IPO |
| 3 | Neuralink | $1.3B | 5 | Active |
| 4 | CMR Surgical | $1.2B | 6 | Active |
| 5 | Neko Health | $1.0B | 3 | Active |
| 6 | Saluda Medical | $680M | 8 | IPO |
| 7 | Aidoc | $524M | 9 | Active |
| 8 | Mevion Medical Systems | $516M | 9 | Active |
| 9 | RefleXion Medical | $493M | 7 | Active |
| 10 | CeQur | $492M | 6 | Active |

In our market report about medical devices, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.
How much money has been invested in MedTech startups?
The 97 startups in our MedTech ranking represent approximately $30.1B in cumulative funding. The ten largest fundraising histories account for $9.405B, showing how much capital has accumulated around a relatively small group of companies.
The top five alone have raised $6.7B, approximately 22.3% of the overall total. What's particularly interesting is that this money has gone into very different technologies. MiRus and Freenome have raised the same amount, for example, despite one developing medical implants and the other working on blood-based cancer screening.
Further down the ranking, funding levels look quite different. GeneCast has raised $22M across four rounds, while several companies between $100M and $200M have already developed specialized products in areas such as pathology, cardiac diagnostics, and robotic surgery.
There is room for both extremes in MedTech. A handful of companies attract enormous commitments because of their ambitions and development costs, while smaller specialists can build valuable businesses around much narrower clinical applications.
Is MedTech funding growing again?
Yes. MedTech financing has recovered substantially, although much of the headline growth comes from public markets, debt, and large strategic transactions rather than a broad-based startup funding boom.
EY's 2026 Pulse of the MedTech Industry report puts sector financing at $63B for the twelve months ending June 2026, an 87% increase year over year. However, IPOs and debt accounted for around 80% of that capital. That's a very different picture from a widespread recovery in venture funding.
HSBC Innovation Banking's 2026 Mid-Year Healthcare Venture Report provides a more specific view of private investment. Medical-device venture funding was slightly below 2025's record pace, but remained above 2023 and 2024 levels. There were 24 medical-device financings of at least $50M during the first half of 2026.
Several large transactions fit this trend. Neko Health raised $700M in July 2026, Precision Neuroscience secured $250M in September, and Medical Microinstruments completed a $125M Series D in October.
The recovery is real, particularly for companies with established clinical programs or credible plans to expand commercially. Early-stage startups without strong clinical evidence are unlikely to benefit equally from the return of large financing rounds.

Our document detailing everything you need to know about medtech gets updated several times a month, so you always get the latest view of where things stand.
What are the biggest MedTech funding rounds?
MiRus's $1.5B strategic investment from Boston Scientific is the largest individual financing event among the companies in our ranking. Neko Health's $700M Series C and Neuralink's $650M Series E are the next major examples, followed by CMR Surgical's $400M strategic preferred equity round in October 2026 and several rounds between $100M and $300M.
MiRus is particularly unusual because the $1.5B transaction represents almost all of its reported $1.6B cumulative funding. Boston Scientific acquired approximately 34% of the privately held company and received an option to acquire its transcatheter aortic valve business, subject to further milestones.
The other large rounds reflect different financing needs. Neko Health's $700M is intended to support international expansion and its US launch. Neuralink's $650M supports further development and patient access for its brain-computer interface technology. Harbinger Health's $100M Series B-II and Precision Neuroscience's $250M Series D show that large investments also reach companies still advancing complex clinical technologies.
| Startup | Total raised | Latest or major round | Date |
|---|---|---|---|
| MiRus | $1.6B | $1.5B | May 2026 |
| Freenome | $1.6B | $240M | July 2026 |
| Neuralink | $1.3B | $650M | June 2025 |
| Neko Health | $1.0B | $700M | July 2026 |
| CMR Surgical | $1.2B | $400M | October 2026 |
| Science Corporation | $416M | $230M | March 2026 |
| Precision Neuroscience | $406M | $250M | September 2026 |
| Medical Microinstruments | $335M | $125M | October 2026 |
| Lumicell | $320M | $198M | May 2025 |
| Exo | $308M | $220M | July 2021 |
| Harbinger Health | $290M | $100M | January 2025 |
Why did MiRus receive a $1.5B investment from Boston Scientific?
MiRus attracted $1.5B from Boston Scientific because of its cardiovascular and orthopedic technology portfolio, particularly its SIEGEL transcatheter aortic valve replacement system. The transaction gives Boston Scientific an approximately 34% equity stake and an option to acquire the valve business after specified clinical and regulatory milestones.
The May 2026 SEC filing provides an unusually clear account of the deal. Boston Scientific paid $1.5B for its equity interest and option, in addition to a $100M payment made previously. It also negotiated potential additional payments of $3B for the valve business if the relevant milestones are achieved and the option is exercised.
This is a very different investment profile from a conventional venture round. Boston Scientific is obtaining a substantial ownership interest and a possible route into a specific clinical market where it sees strategic value.
One distinction is important when interpreting MiRus's funding position: its $1.6B cumulative total reflects the recorded financing history, while the additional $3B represents potential future acquisition payments rather than money already raised.

In our report covering the medtech market, we look at what the winners do differently, so you can learn from the best instead of guessing.
How much funding has Freenome raised, and is it publicly traded?
Freenome has raised $1.6B across ten rounds and is now publicly traded on Nasdaq under the ticker FRNM. Its July 2026 public listing followed a business combination with Perceptive Capital Solutions.
The transaction included a $240M PIPE, led by Perceptive Advisors and RA Capital. Freenome also received proceeds from the SPAC trust account, bringing total gross proceeds associated with the transaction to more than $300M.
Freenome develops blood-based cancer screening tests using multiomics, artificial intelligence, and machine learning. Its public-market transition came alongside important clinical developments: in July 2026, the company reported that an updated version of its SimpleScreen colorectal cancer screening test met its primary and secondary endpoints.
The company now has to demonstrate that its technology can move from clinical validation to sustained commercial adoption. Abbott's involvement in commercializing the colorectal screening test in the US provides an important route into the market.
Freenome's funding history is particularly interesting because it combines extensive private fundraising with a public-market transaction. Its IPO status should therefore be considered when comparing it with privately held MedTech startups.
Is Neuralink still the best-funded brain-computer interface startup?
Yes. Neuralink leads the brain-computer interface companies in our ranking with $1.3B raised across five rounds. Its $650M Series E in June 2025 was backed by investors including Founders Fund, ARK Invest, Sequoia Capital, QIA, and Thrive Capital.
The gap with its closest competitors is substantial. Science Corporation has raised $416M, Precision Neuroscience $406M, and Synchron $325M. Neuralink's cumulative funding is therefore greater than the combined $1.147B raised by those three companies.
However, their technologies are quite different. Neuralink develops implantable brain-computer interfaces, Synchron uses an endovascular approach to reach the brain, and Precision Neuroscience focuses on minimally invasive neural interfaces. Science Corporation also develops retinal implants.
The clinical challenge is significant. These companies must demonstrate long-term safety, reliable communication between the brain and external devices, and meaningful benefits for patients. Neuralink's financing advantage gives it considerable resources to pursue those goals, but it does not automatically establish that its technology will become the preferred clinical approach.

Theory only gets you so far. In our research about medical devices, we dig up the real signals from the field and show you the ones worth watching.
Which surgical robotics startups have raised the most money?
CMR Surgical leads surgical robotics in our ranking with $1.2B raised, followed by Edge Medical Robotics at $462M and Cornerstone Robotics at $460M. Medical Microinstruments, Distalmotion, and THINK Surgical have also attracted substantial investment.
The companies cover several distinct surgical applications. CMR Surgical develops its Versius robotic system for minimally invasive surgery, while Medical Microinstruments focuses on microsurgery using its Symani system. THINK Surgical targets orthopedic procedures, and Distalmotion develops robotic-assisted systems for minimally invasive surgery.
Recent transactions show that investor interest remains strong. CMR Surgical raised $400M in strategic preferred equity and Medical Microinstruments $125M in October 2026, while Medtronic announced a major strategic partnership with Cornerstone Robotics in September 2026.
CMR Surgical's April 2025 financing also deserves attention. The company announced a round exceeding $200M, combining equity and debt, with Trinity Capital providing up to $68.75M in growth capital. This illustrates why equity investment and debt need to be distinguished when comparing fundraising histories.
Surgical robotics remains one of the most capital-intensive areas of MedTech. Companies must develop sophisticated hardware, obtain regulatory approvals, build distribution networks, train surgeons, and persuade hospitals to invest in expensive equipment. Getting the robot into the operating room is only part of the job.
Are medical AI startups attracting more funding than medical-device companies?
Medical AI startups are attracting substantial funding, but the broader medical-device category still includes some of the largest financing histories in our ranking. Aidoc has raised $524M, Cleerly $403M, PathAI $258M, and Viz.ai $254M, while MiRus, Neuralink, and CMR Surgical each exceed $1B.
These companies also have different business models. Aidoc develops AI-powered medical imaging diagnostics, Cleerly focuses on cardiovascular imaging, PathAI works on digital pathology, and Viz.ai combines disease detection with clinical coordination.
Medical AI software can potentially scale across multiple hospitals without requiring a complex physical device for every customer. But selling into healthcare is still difficult. Companies need clinical validation, integration with hospital systems, regulatory authorization, and a convincing financial case for adoption.
The FDA's AI-enabled medical-device list contained more than 1,600 authorized devices as of September 2026. That's a substantial indication of how quickly AI has entered regulated healthcare products.
Medical AI has become a major MedTech investment category, particularly in imaging and diagnostics. Its fundraising totals, however, should be compared with software businesses rather than automatically treated as equivalent to the economics of implantable devices or surgical robots.

In our market report about medical devices, we don't want to repeat what boring consulting reports say. Instead, we show you the real and latest market signals that matter.
Which MedTech startups are leading AI medical diagnostics?
Aidoc leads the AI medical diagnostics companies in our ranking with $524M raised across nine rounds, including a $150M Series E in April 2026. Cleerly follows with $403M, PathAI has raised $258M, and Viz.ai has accumulated $254M.
The market is becoming increasingly specialized. Aidoc concentrates on medical imaging diagnostics, Cleerly analyzes cardiovascular imaging, PathAI develops digital pathology technology, and Viz.ai works on disease detection and coordination between healthcare professionals.
Other important companies include Iterative Health, which has raised $264M for AI-assisted gastrointestinal diagnostics, and Elucid, which has raised $185M for cardiovascular imaging software.
Regulatory progress is helping establish the category. The FDA's list of authorized AI-enabled medical devices includes products across radiology, cardiology, pathology, and other clinical specialties. Aidoc itself has continued expanding its regulatory footprint, including receiving additional FDA Breakthrough Device Designation in June 2026.
The challenge now is commercial. Hospitals already have access to many imaging and diagnostic tools, so AI developers must demonstrate that their software improves clinical decisions or makes workflows sufficiently faster and more efficient to justify another technology purchase.
Which cancer-detection startups have raised the most money?
Freenome leads the cancer-detection startups in our ranking with $1.6B raised, followed by DELFI Diagnostics at $331M and Harbinger Health at $290M. Their financing histories show how much investor interest has developed around blood-based cancer screening and early detection.
Freenome uses multiomics and AI to develop blood-based screening tests. Harbinger Health is also developing blood-based early cancer detection, while DELFI Diagnostics applies machine learning to cell-free DNA fragment patterns.
Other companies are pursuing more specific applications. Geneoscopy has raised $156M for RNA-based colorectal cancer screening, and GeneCast has raised $22M for liquid-biopsy diagnostics.
The financing gap between Freenome and the other companies is striking. Freenome's $1.6B represents more than five times Harbinger Health's $290M, but that difference does not prove its technology is five times more effective.
The real test is whether these products can demonstrate sufficient accuracy in large clinical populations, obtain regulatory authorization, and convince healthcare systems and insurers that screening produces measurable benefits.
Freenome's July 2026 clinical results and its commercial relationship with Abbott give it an important opportunity to advance beyond development. The wider early-detection market still has substantial clinical and economic questions to resolve.

Learning from others' mistakes is the cheapest lesson there is. In our document detailing everything you need to know about medtech, we look at what broke startups before you, so you don't repeat it.
Which cardiovascular MedTech startups have attracted the most funding?
MiRus leads the cardiovascular-related companies in our ranking with $1.6B raised, followed by Imperative Care at $446M and Cleerly at $403M. The wider group includes startups developing heart valves, stroke intervention devices, cardiac imaging, and heart failure treatments.
Several companies are focused on minimally invasive interventions. JenaValve has raised $349M for transcatheter aortic valve replacement, Cardiac Dimensions $275M for heart failure treatments, and 4C Medical Technologies $250M for heart valve replacement.
Other companies are working on specialized monitoring and diagnostic technologies. FIRE1 has raised $201M for remote heart failure monitoring, while Elucid has secured $185M for cardiovascular imaging software.
Recent financing also remains active. Pulnovo Medical recorded a $100M Series D / strategic equity round in April 2026, and HighLife Medical secured $92M in growth equity in September 2026.
HSBC Innovation Banking reported that cardiovascular investment was weaker in the first half of 2026 than in the previous year, even as investment in neurotechnology, imaging, and non-invasive monitoring increased.
Capital continues to support technologies that could improve diagnosis or make complex procedures less invasive. Competition is particularly intense in cardiovascular medicine, where companies are targeting specific clinical problems rather than trying to build one solution for every patient.
Which MedTech startups have raised funding most recently?
CMR Surgical, Medical Microinstruments, ZAP Surgical Systems, Precision Neuroscience, and HighLife Medical are among the companies with the most recent financing rounds in our ranking. Their latest recorded transactions span surgical robotics, radiosurgery, neural interfaces, and cardiovascular devices.
Medical Microinstruments completed a $125M Series D in October 2026, bringing its cumulative funding to $335M. ZAP Surgical Systems recorded a $36M Series F in October, taking its reported minimum total to $195M.
September was also active. Precision Neuroscience raised $250M in a Series D, Elucid secured $55M in a Series D, and HighLife Medical raised $92M in growth equity. Synchron also completed a Series D extension, although the amount was undisclosed.
These transactions show that major financing activity continues across different MedTech specialties. Some companies are expanding commercial operations, while others are financing the next stage of clinical development.
| Startup | Latest round | Amount | Date |
|---|---|---|---|
| Cornerstone Robotics | Strategic Investment | Undisclosed | September 2026 |
| Precision Neuroscience | Series D | $250M | September 2026 |
| Medical Microinstruments | Series D | $125M | October 2026 |
| CMR Surgical | Strategic Preferred Equity | $400M | October 2026 |
| Synchron | Series D Extension | Undisclosed | September 2026 |
| Beacon Biosignals | Series B-2 | $110M | September 2026 |
| ZAP Surgical Systems | Series F | $36M | October 2026 |
| Elucid | Series D | $55M | September 2026 |
| HighLife Medical | Growth Equity | $92M | September 2026 |

If you build or invest in the medtech market, you need to know which business models pay off now and which ones are fading. That's why our report covering it has a whole section on it.
Who are the biggest investors in MedTech startups?
Boston Scientific, Medtronic, General Catalyst, Khosla Ventures, and Novo Holdings are among the most prominent investors across the MedTech startups in our ranking. Their investments cover medical devices, diagnostic software, surgical robotics, and advanced therapeutic technologies.
Boston Scientific has the most visible strategic position through its $1.5B investment in MiRus and its participation in 4C Medical Technologies' $71.6M Series D.
Medtronic has backed companies working on surgical robotics and cardiovascular intervention, including Cornerstone Robotics and Pulnovo Medical.
Among financial investors, General Catalyst appears in the funding histories of Aidoc, Sword Health, SetPoint Medical, and Corvia Medical. Khosla Ventures is associated with Science Corporation, Sword Health, Karius, and AliveCor. Novo Holdings appears among the investors in Quanta Dialysis Technologies, Supira Medical, Route 92 Medical, and Magenta Medical.
These repeated investments show how large healthcare-focused investors build exposure across multiple medical specialties. Industrial companies often look for technologies that complement their existing businesses, while venture investors can spread their capital across diagnostics, devices, and digital healthcare.
One distinction is worth keeping in mind: an investor appearing among a company's key backers does not necessarily mean it contributed the largest share of its cumulative financing.
Which countries have the most heavily funded MedTech startups?
The United States has the strongest presence in our MedTech funding ranking, with several of the largest companies based there. However, some of the most heavily financed startups come from the UK, Sweden, Switzerland, Israel, and China.
The US has MiRus and Freenome at $1.6B each, Neuralink at $1.3B, and several other companies above $400M. The UK's CMR Surgical has raised $1.2B, while Sweden's Neko Health has reached $1.0B.
Switzerland is represented by CeQur at $492M and Distalmotion at $300M. Israel has Aidoc at $524M, while China's Edge Medical Robotics has raised $462M.
The differences between countries are also visible in the technologies being developed. The UK has a strong presence in surgical robotics and dialysis technology. Israel has several companies in medical imaging and diagnostics. China has attracted substantial funding in robotic surgery, glucose monitoring and imaging AI.
The US remains the clear center of capital concentration, but European and Asian companies are building substantial businesses in specialized clinical markets.

In our research about medical devices, we like to show you the big picture. We know your time is precious, so we make every page quick to read and packed with as much learning as possible per minute.
Can European MedTech startups compete with American companies?
Yes. European MedTech startups can attract financing on a comparable scale to many American companies, although the US still dominates the upper end of the funding ranking.
CMR Surgical has raised $1.2B, Neko Health has reached $1.0B, and Switzerland's CeQur has secured $492M. Other European examples include Quanta Dialysis Technologies at $410M, DentalMonitoring at $307M, and Distalmotion at $300M.
There is also a strong group of smaller specialists. The Netherlands' Xeltis has raised $216M for regenerative implants, Ireland's FIRE1 has secured $201M for heart failure monitoring, and France's HighLife Medical has reached $144M.
European companies are active in several areas where medical expertise and engineering capabilities are particularly important. These include robotic surgery, cardiovascular devices, remote monitoring, and preventive diagnostics.
Their biggest challenge is scaling internationally. US companies generally have direct access to the world's largest medical-device market, while European startups often need to navigate multiple healthcare systems, procurement processes, and reimbursement structures.
The financing histories show that European startups can attract substantial capital. Their long-term competitiveness will depend on converting that funding into broad clinical adoption and international sales.
Are preventive health scanning startups becoming a major MedTech category?
Yes. Preventive scanning is attracting large amounts of private investment, led by Neko Health, which has raised $1.0B, and Prenuvo, which has secured $176M.
Neko Health's $700M Series C in July 2026 was particularly significant. The company combines proprietary scanning technology, clinical assessments, and in-person health services. It is also expanding into the US, with its financing intended to support that launch.
Prenuvo takes a different approach, focusing on whole-body MRI screening. Its $120M Series B in February 2025 brought its cumulative funding to $176M.
Both companies are targeting consumers who want more information about their health before symptoms appear. This creates a potentially large market, particularly among people willing to pay directly for preventive services.
However, the clinical questions remain important. Whole-body screening can generate incidental findings and false positives, while the benefits of repeated examinations for otherwise healthy people are not established equally across all applications.
Neko Health has attracted considerably more funding, but the broader preventive health market still needs to demonstrate that consumer demand can translate into sustainable economics and meaningful improvements in health outcomes.

When you build or invest in the medtech market, you need clarity, not confusion. In our market report about medical devices, we always try to put numbers on and quantify whatever is usually vague and confusing.
Are wearable medical-device startups still attracting serious funding?
Yes. Wearable medical technologies continue attracting substantial investment, especially when they address specific medical needs such as diabetes management, cardiac monitoring, and remote examinations.
CeQur leads the wearable-related companies in our ranking with $492M raised for insulin delivery devices. Biolinq has secured $247M for continuous biomarker monitoring, while SIBIONICS has raised $226M for glucose monitoring and biosensors.
Remote monitoring is another important area. TytoCare has raised $229M for remote medical examinations, while Eko Health has accumulated $168M for AI-enabled cardiac monitoring.
The companies are pursuing different business models. Continuous glucose monitoring and insulin delivery involve recurring use of physical medical products, while remote examination platforms depend more heavily on digital services and healthcare-provider integration.
VitalConnect, now acquired, has raised at least $148M for wearable cardiac and patient monitoring. Its history also shows that wearable medical technologies can become acquisition targets for established healthcare businesses.
Connected medical devices continue to attract investment, especially where the technology fits naturally into ongoing patient care. Generic health tracking faces a much harder commercial test than products that address a clearly defined medical requirement.
Are MedTech IPOs and acquisitions becoming more common again?
Yes. Public listings and acquisitions have become more important exit routes for MedTech startups, although the recovery is concentrated in a relatively small number of transactions.
EY's 2026 MedTech report put disclosed M&A deal value at approximately $130B for the year ended June 2026, the highest level in more than a decade. However, a limited number of large transactions accounted for much of that amount.
Our ranking includes several companies that have already reached public markets. Freenome has raised $1.6B and is now listed on Nasdaq. Saluda Medical has raised $680M and completed an IPO, while Edge Medical Robotics has raised $462M and also went public.
Acquisitions are another important outcome. Nalu Medical, now acquired, has raised $201M, and VitalConnect, now acquired, has raised at least $148M.
HSBC's first-half 2026 report also identified twelve venture-backed medical-device M&A transactions during the period, with a median upfront payment of $345M.
The reopening of exit opportunities gives investors more ways to realize returns. It also gives established medical-device manufacturers an opportunity to acquire technologies that would take considerable time and resources to develop internally.
Does raising more money make a MedTech startup more successful?
No. A large funding total shows that investors have committed substantial capital to a company, but it does not guarantee that the technology will work commercially or that patients will benefit.
Freenome, Saluda Medical, and Edge Medical Robotics have gone public after raising $1.6B, $680M, and $462M, respectively. Nalu Medical and VitalConnect have been acquired after raising $201M and at least $148M.
Sight Diagnostics offers a very different outcome. The Israeli diagnostics company raised $124M across five rounds, including a $71M Series D in July 2020, but has since shut down.
Clinical development is a particularly difficult part of MedTech. The FDA reported 1,320 Breakthrough Device designations as of June 30, 2026, but only 210 devices had received marketing authorization for indications consistent with those designations.
That gap shows how much work can remain after a technology receives a favorable regulatory designation. Companies still need clinical evidence, manufacturing capabilities, reimbursement, and commercial adoption.
Funding is a useful way to measure investor commitment. It is a much less reliable way to predict which MedTech startups will ultimately become successful businesses.
Is it becoming harder for MedTech startups to commercialize their products?
Commercializing medical technology remains difficult, particularly for companies developing implantable devices, surgical robots, and complex diagnostic systems. Regulatory approval is only one part of the process; companies must also secure reimbursement, hospital adoption, and enough clinical evidence to convince healthcare professionals to change established practices.
CMR Surgical's $1.2B funding history illustrates the cost of building and selling surgical robotics. Neuralink's $1.3B reflects the long development path of implantable brain-computer interfaces, while RefleXion Medical has raised $493M for advanced cancer radiotherapy.
Medical AI companies face a different set of challenges. Aidoc has raised $524M and has made substantial regulatory and commercial progress, but hospitals still need to integrate its software into clinical workflows and justify the recurring cost.
There has been a recent attempt to address the reimbursement bottleneck. In April 2026, CMS and the FDA announced the RAPID coverage pathway, designed to improve the alignment between FDA authorization and Medicare coverage for eligible breakthrough devices. CMS published further details in August 2026.
This could make a meaningful difference for startups approaching commercialization. Faster coverage decisions will still depend on evidence that a device improves clinical outcomes, though. Regulatory progress alone won't convince hospitals or insurers to pay for a new technology.
Which MedTech startups could attract the most funding next?
Neurotechnology, medical AI, surgical robotics, and minimally invasive cardiovascular devices look particularly well positioned to attract further investment. Recent rounds show that investors are still willing to commit hundreds of millions of dollars when a company has a convincing clinical opportunity and a clear development plan.
Precision Neuroscience's $250M Series D in September 2026 and Science Corporation's $230M Series C in March 2026 illustrate continued interest in brain-computer interfaces and neural technology.
Medical AI also remains active. Aidoc raised $150M in April 2026, while Iterative Health secured $77M in its Series C during the same month.
Surgical robotics continues to attract strategic and financial backing. Medical Microinstruments raised $125M in October 2026, and Cornerstone Robotics secured a major strategic partnership with Medtronic in September.
Cardiovascular devices remain part of the picture, with Pulnovo Medical raising $100M in April and HighLife Medical securing $92M in September.
The companies most likely to attract further funding will be those able to demonstrate clinical progress and a credible route to revenue. Investors are still interested in ambitious technologies, but they increasingly need to see how those technologies will reach patients and generate sustainable returns.
Who is actually winning the MedTech funding race?
MiRus and Freenome are the joint leaders in cumulative funding at $1.6B each, followed by Neuralink at $1.3B, CMR Surgical at $1.2B, and Neko Health at $1.0B. These five companies have attracted $6.7B combined, but their different technologies make it difficult to identify a single overall winner.
MiRus has benefited from an exceptional strategic investment from Boston Scientific. Freenome has built a substantial financing history around blood-based cancer screening and has now entered the public markets. Neuralink has attracted considerable backing for brain-computer interfaces, while CMR Surgical has secured capital to develop and commercialize robotic surgery.
Neko Health's $700M Series C also shows that preventive healthcare can attract financing on a scale traditionally associated with advanced medical devices and biotechnology.
The broader market contains a much wider range of companies. Aidoc, RefleXion Medical, CeQur, Imperative Care, Science Corporation, and Precision Neuroscience all demonstrate substantial investor interest in specialized clinical technologies.
Our judgment is that MedTech has several clear funding leaders, but the market remains divided across very different clinical and commercial opportunities. The companies that eventually pull ahead will be those that turn their financing into approved products, strong clinical results, reimbursement, and repeatable sales.
Our methodology
This analysis ranks startups in the MedTech market by total funding raised. We examine their financing histories, major investment rounds, clinical specialties, geographical distribution, public listings, and acquisitions to understand where capital is going and which companies are attracting the largest commitments.
We distinguish strategic investments, venture financing, debt, and potential future acquisition payments where relevant. In particular, MiRus's potential additional $3B in milestone-based acquisition payments is not counted as funding already raised.
Key sources include EY's 2026 Pulse of the MedTech Industry report, HSBC Innovation Banking's 2026 Mid-Year Healthcare Venture Report, SEC filings covering Boston Scientific's investment in MiRus, Freenome's public-market transaction and clinical announcements, company financing announcements, FDA data on AI-enabled medical devices and Breakthrough Device designations, and CMS/FDA materials on the RAPID coverage pathway.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
